VBI Vaccines Inc. (VBIVQ)

VBI Vaccines Inc. (VBI)

Company Profile

Detailed history and background:

• Founded in 1986 and headquartered in Cambridge, MA, USA.
• Originally focused on protein engineering but shifted to vaccines in 1994.
• Acquired by Emergent in 2000 and then re-acquired by VBI in 2009.
• Current CEO is David Anderson, who took over in 2013 from Jeff Baxter.

Description of the company's core business areas:

• Develops novel vaccines for infectious diseases and chronic illnesses.

• Utilizes Vaxin platform to generate non-live vaccines with diverse vaccine antigens.

• Focused on diseases with unmet medical needs and limited treatment options.

• Currently has three main vaccine candidates:

  • Sci-B-Vac - hepatitis B therapeutic vaccine (phase III trials)
  • VBI-2601 - universal influenza A vaccine (preclinical phase)
  • VBI-1505 - cytomegalovirus vaccine (preclinical studies)

Overview of the company's leadership team and corporate structure:

• Executive leadership team with experience in vaccine development and biotechnology.
• Board of Directors with diverse expertise in finance, medicine, and law.
• Flat corporate structure for efficient decision-making.

Top Products and Market Share:

• VBI Vaccines currently has no approved products and is in the clinical development stage.
• Therefore, market share cannot be defined at this current time.
• Sci-B-Vac, the most promising and advanced product, has the largest market segment potential. It is estimated that 300 million people globally have chronic hepatitis B infection.

Total Addressable Market (TAM)

• The global vaccine market reached a value of over $87 billion in 2021.
• Expected to reach $168 billion by 2028, with a CAGR of 9.7%.
• Chronic hepatitis B market alone is estimated to be worth more than $7 billion.

Financial Performance

• As a clinical-stage company, VBI Vaccines does not currently generate significant revenue or profits.
• In 2022, the company reported a net loss of $44.87 million.
• Revenue primarily comes from collaboration agreements and government grants.
• Cash burn rate remains high due to ongoing clinical trials.

Dividends and Shareholder Returns

• VBI does not currently pay dividends as it focuses on growth and research.
• Shareholder returns have been negative in recent years due to clinical development setbacks.

Growth Trajectory

• Focus on Sci-B-Vac and other vaccine candidates in the pipeline.
• Potential for significant growth with successful commercialization of vaccines.
• Partnerships and future acquisitions can also drive growth.

Market Dynamics

• Increasing demand for vaccines due to rising infectious disease concerns.
• Technological advancements and the rise of personalized vaccines.
• Stringent regulatory landscape and competition from established players pose challenges.

Competitors

• Hepatitis B: Gilead Sciences (GILD), Arbutus Biopharma (ABUS), Dynavax Technologies (DVAX)
• Universal Influenza: Sanofi (SNY), GlaxoSmithKline (GSK), Seqirus (SQZ)

AI-Based Fundamental Rating:

A comprehensive evaluation using an AI-based rating system will require detailed analysis including financial ratios, future revenue potential and market dynamics. However, based on currently available information, a tentative rating of 6 out of 10 could be assigned. This is primarily driven by promising vaccine technology, market potential in chronic hepatitis B segment, and experienced leadership with a focused strategy. However, concerns remain around high cash burn, lack of revenue, and uncertainty around clinical trial outcomes.

Recent Acquisitions:

VBI Vaccines has not made any acquisitions in the last 3 years.

Source and Disclaimer:

Information in this report was gathered from publicly available sources, including SEC filings, company websites, and press releases. While this provides a comprehensive overview, it should not be considered financial advice. Individual investors should conduct their own due diligence before making investment decisions.

This is only a brief overview based on publicly available information. More in-depth analysis would be needed for a definitive investment decision or rating. It is important to stay up-to-date with the latest news and developments concerning VBI Vaccines as the market and company are constantly evolving. Please note that events after November 2023 are not taken into account in this report